Supplementary Table S4 The comprehensive detailed information of all AEs at the PTs level identified by BCPNN algorithms.

|  |  |  |  |
| --- | --- | --- | --- |
| Preferred Terms | SOC | Case Number | IC(IC025) |
| Heterochromia iridis | Eye disorders | 7 | 10.78 (8.13) |
| Choroidal dystrophy | Eye disorders | 9 | 10.25 (8) |
| Iris atrophy | Eye disorders | 15 | 9.46 (7.75) |
| Retinal degeneration | Eye disorders | 15 | 8.88 (7.21) |
| Enophthalmos | Eye disorders | 8 | 9.39 (7.15) |
| Alveolar soft part sarcoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 4 | 9.34 (6.42) |
| Febrile bone marrow aplasia | General disorders and administration site conditions | 30 | 7.48 (6.3) |
| Brain stem glioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 5 | 8.49 (5.9) |
| Proteus test positive | Investigations | 4 | 8.2 (5.42) |
| Arteriosclerotic retinopathy | Vascular disorders | 3 | 8.26 (5.19) |
| Iris adhesions | Eye disorders | 7 | 7.37 (5.15) |
| Lenticular opacities | Eye disorders | 6 | 7.35 (5) |
| Cerebral cyst | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 8 | 6.83 (4.75) |
| Nephroblastoma | Renal and urinary disorders | 3 | 7.73 (4.71) |
| Vitreous haemorrhage | Eye disorders | 18 | 6.17 (4.7) |
| Neutrophil count decreased | Investigations | 103 | 5.28 (4.62) |
| Small cell lung cancer | Respiratory, thoracic and mediastinal disorders | 12 | 6.32 (4.57) |
| Ocular toxicity | Eye disorders | 7 | 6.65 (4.46) |
| Red blood cell count decreased | Investigations | 62 | 5.06 (4.23) |
| Acute febrile neutrophilic dermatosis | Skin and subcutaneous tissue disorders | 12 | 5.92 (4.18) |
| Cataract subcapsular | Eye disorders | 5 | 6.61 (4.12) |
| Myelosuppression | Blood and lymphatic system disorders | 8 | 6.13 (4.06) |
| Chorioretinal disorder | Eye disorders | 3 | 7.01 (4.03) |
| Haematotoxicity | Blood and lymphatic system disorders | 23 | 5.18 (3.87) |
| Scleritis | Immune system disorders | 7 | 6.01 (3.83) |
| Monocyte count decreased | Investigations | 5 | 6.13 (3.65) |
| Intracranial tumour haemorrhage | Nervous system disorders | 3 | 6.58 (3.62) |
| Neuroblastoma | Endocrine disorders | 3 | 6.56 (3.6) |
| Subileus | Gastrointestinal disorders | 7 | 5.65 (3.47) |
| Protein total decreased | Investigations | 10 | 5.35 (3.47) |
| White blood cell count decreased | Investigations | 127 | 4 (3.4) |
| Acute interstitial pneumonitis | Respiratory, thoracic and mediastinal disorders | 3 | 6.32 (3.36) |
| Ileus | Gastrointestinal disorders | 22 | 4.6 (3.26) |
| Anaemia | Blood and lymphatic system disorders | 187 | 3.74 (3.24) |
| Platelet count decreased | Investigations | 113 | 3.87 (3.24) |
| Febrile neutropenia | General disorders and administration site conditions | 63 | 3.98 (3.15) |
| Disease progression | General disorders and administration site conditions | 123 | 3.69 (3.08) |
| Thrombocytopenia | Blood and lymphatic system disorders | 101 | 3.62 (2.96) |
| Malignant ascites | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 3 | 5.74 (2.8) |
| Conjunctival oedema | Eye disorders | 4 | 5.44 (2.76) |
| White blood cells urine positive | Investigations | 4 | 5.43 (2.75) |
| Pancytopenia | Blood and lymphatic system disorders | 50 | 3.63 (2.72) |
| Neutropenic sepsis | Blood and lymphatic system disorders | 12 | 4.36 (2.62) |
| Retinal ischaemia | Eye disorders | 3 | 5.56 (2.62) |
| Hospice care | Surgical and medical procedures | 13 | 4.3 (2.62) |
| Neutropenia | Blood and lymphatic system disorders | 86 | 3.26 (2.54) |
| Thrombocytosis | Blood and lymphatic system disorders | 3 | 5.42 (2.48) |
| Blood phosphorus increased | Investigations | 5 | 4.88 (2.42) |
| Autonomic neuropathy | Nervous system disorders | 3 | 5.35 (2.41) |
| Metastases to central nervous system | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 15 | 3.96 (2.38) |
| Platelet transfusion | Surgical and medical procedures | 3 | 5.28 (2.35) |
| Ovarian cancer metastatic | Reproductive system and breast disorders | 3 | 5.22 (2.28) |
| Hydronephrosis | Renal and urinary disorders | 10 | 4.14 (2.27) |
| Blood chloride decreased | Investigations | 5 | 4.69 (2.23) |
| Retinopathy | Vascular disorders | 7 | 4.33 (2.17) |
| Leukopenia | Blood and lymphatic system disorders | 34 | 3.21 (2.11) |
| Carbohydrate antigen 125 increased | Investigations | 6 | 4.41 (2.11) |
| Ocular vascular disorder | Eye disorders | 3 | 5.04 (2.11) |
| Large intestine perforation | Injury, poisoning and procedural complications | 9 | 4.06 (2.1) |
| Malignant neoplasm progression | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 57 | 2.94 (2.08) |
| Blood culture positive | Investigations | 6 | 4.37 (2.07) |
| Conjunctival hyperaemia | Eye disorders | 6 | 4.33 (2.03) |
| Pulmonary toxicity | Respiratory, thoracic and mediastinal disorders | 8 | 4 (1.95) |
| Blood test abnormal | Investigations | 12 | 3.63 (1.9) |
| Hypomagnesaemia | Metabolism and nutrition disorders | 12 | 3.6 (1.87) |
| VIth nerve paralysis | Nervous system disorders | 3 | 4.79 (1.86) |
| Mucosal inflammation | General disorders and administration site conditions | 18 | 3.29 (1.84) |
| Haemoglobin decreased | Investigations | 50 | 2.73 (1.82) |
| Hypoproteinaemia | Hepatobiliary disorders | 3 | 4.74 (1.82) |
| Pulmonary haemorrhage | Vascular disorders | 9 | 3.72 (1.76) |
| Blood urea increased | Investigations | 14 | 3.38 (1.75) |
| Pyelonephritis | Renal and urinary disorders | 8 | 3.76 (1.71) |
| Neoplasm progression | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 24 | 2.98 (1.7) |
| Conjunctival haemorrhage | Eye disorders | 6 | 3.99 (1.69) |
| Dehydration | Metabolism and nutrition disorders | 54 | 2.47 (1.59) |
| Ascites | Cardiac disorders | 18 | 3.01 (1.55) |
| Red blood cell transfusion | Surgical and medical procedures | 3 | 4.47 (1.55) |
| General physical health deterioration | General disorders and administration site conditions | 43 | 2.52 (1.54) |
| Decreased appetite | Metabolism and nutrition disorders | 82 | 2.23 (1.50) |
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | 29 | 2.62 (1.45) |
| Venous thrombosis | Vascular disorders | 5 | 3.9 (1.44) |
| Radiation pneumonitis | Respiratory, thoracic and mediastinal disorders | 3 | 4.34 (1.42) |
| Rash vesicular | Skin and subcutaneous tissue disorders | 5 | 3.87 (1.41) |
| Metastases to meninges | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 3 | 4.32 (1.4) |
| Protein urine present | Investigations | 5 | 3.85 (1.39) |
| Renal tubular disorder | Renal and urinary disorders | 4 | 4.03 (1.37) |
| Posterior reversible encephalopathy syndrome | Nervous system disorders | 8 | 3.42 (1.36) |
| Interstitial lung disease | Immune system disorders | 22 | 2.69 (1.36) |
| Aspergillus infection | Infections and infestations | 3 | 4.16 (1.24) |
| Lymphopenia | Blood and lymphatic system disorders | 9 | 3.19 (1.23) |
| Septic shock | Vascular disorders | 18 | 2.66 (1.2) |
| Hyponatraemia | Metabolism and nutrition disorders | 24 | 2.46 (1.18) |
| Performance status decreased | General disorders and administration site conditions | 5 | 3.63 (1.18) |
| Escherichia infection | Infections and infestations | 6 | 3.47 (1.17) |
| Blood lactic acid increased | Investigations | 5 | 3.61 (1.15) |
| Pyrexia | General disorders and administration site conditions | 89 | 1.82 (1.12) |
| Hyperammonaemia | Hepatobiliary disorders | 5 | 3.56 (1.1) |
| Toxicity to various agents | Injury, poisoning and procedural complications | 13 | 2.78 (1.1) |
| Cardiac dysfunction | Cardiac disorders | 3 | 3.96 (1.04) |
| Cerebellar syndrome | Nervous system disorders | 3 | 3.96 (1.04) |
| Death | General disorders and administration site conditions | 247 | 1.47 (1.03) |
| Hypoxia | Respiratory, thoracic and mediastinal disorders | 15 | 2.59 (1.01) |
| Vomiting | Gastrointestinal disorders | 115 | 1.61 (0.98) |
| Blood lactate dehydrogenase increased | Investigations | 9 | 2.92 (0.97) |
| Nausea | Gastrointestinal disorders | 169 | 1.38 (0.86) |
| Bone marrow failure | Blood and lymphatic system disorders | 12 | 2.58 (0.85) |
| Sepsis | Infections and infestations | 32 | 1.95 (0.83) |
| Full blood count decreased | Investigations | 9 | 2.78 (0.83) |
| Haematocrit decreased | Investigations | 10 | 2.68 (0.8) |
| Hypotonia | Nervous system disorders | 7 | 2.87 (0.71) |
| Blood albumin decreased | Investigations | 5 | 3.17 (0.71) |
| Blood sodium decreased | Investigations | 9 | 2.66 (0.71) |
| Orthopnoea | Respiratory, thoracic and mediastinal disorders | 3 | 3.61 (0.69) |
| Haemodialysis | Surgical and medical procedures | 7 | 2.84 (0.67) |
| Product use in unapproved indication | Injury, poisoning and procedural complications | 47 | 1.61 (0.67) |
| Papule | Skin and subcutaneous tissue disorders | 4 | 3.3 (0.64) |
| Bone marrow disorder | Blood and lymphatic system disorders | 3 | 3.55 (0.63) |
| Respiratory failure | Metabolism and nutrition disorders | 23 | 1.94 (0.63) |
| Ovarian cancer | Reproductive system and breast disorders | 7 | 2.79 (0.62) |
| Deafness neurosensory | Nervous system disorders | 3 | 3.53 (0.61) |
| Cholestasis | Hepatobiliary disorders | 8 | 2.66 (0.61) |
| Aspartate aminotransferase increased | Investigations | 18 | 2.06 (0.6) |
| Optic ischaemic neuropathy | Eye disorders | 3 | 3.5 (0.58) |
| Pneumonia | Respiratory, thoracic and mediastinal disorders | 63 | 1.38 (0.56) |
| Metastases to bone | Musculoskeletal and connective tissue disorders | 7 | 2.68 (0.52) |
| Abdominal pain | Gastrointestinal disorders | 47 | 1.44 (0.5) |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | 97 | 1.13 (0.45) |
| Failure to thrive | Pregnancy, puerperium and perinatal conditions | 4 | 3.11 (0.45) |
| Blood bilirubin increased | Investigations | 11 | 2.24 (0.44) |
| Blood creatinine increased | Investigations | 19 | 1.85 (0.43) |
| Acute respiratory distress syndrome | Immune system disorders | 8 | 2.48 (0.43) |
| Periorbital oedema | Immune system disorders | 4 | 3.08 (0.42) |
| Atelectasis | Respiratory, thoracic and mediastinal disorders | 5 | 2.86 (0.4) |
| Fatigue | General disorders and administration site conditions | 117 | 1 (0.38) |
| Hepatic lesion | Hepatobiliary disorders | 3 | 3.3 (0.38) |
| Diplopia | Nervous system disorders | 10 | 2.25 (0.37) |
| Gastrointestinal toxicity | Gastrointestinal disorders | 3 | 3.28 (0.36) |
| Platelet count increased | Investigations | 6 | 2.62 (0.32) |
| Recurrent cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 3 | 3.2 (0.28) |
| Acute myeloid leukaemia | Blood and lymphatic system disorders | 7 | 2.44 (0.28) |
| Asthenia | General disorders and administration site conditions | 61 | 1.1 (0.27) |
| Blood magnesium decreased | Investigations | 4 | 2.92 (0.26) |
| Mental status changes | Psychiatric disorders | 11 | 2.06 (0.26) |
| Alanine aminotransferase increased | Investigations | 17 | 1.75 (0.26) |
| Tachypnoea | Respiratory, thoracic and mediastinal disorders | 6 | 2.54 (0.25) |
| Ileus paralytic | Gastrointestinal disorders | 3 | 3.14 (0.22) |
| Confusional state | Psychiatric disorders | 34 | 1.29 (0.2) |
| C-reactive protein increased | Investigations | 9 | 2.14 (0.18) |
| Hypokalaemia | Metabolism and nutrition disorders | 12 | 1.9 (0.17) |
| Multiple organ dysfunction syndrome | General disorders and administration site conditions | 9 | 2.12 (0.16) |
| Oesophageal pain | Gastrointestinal disorders | 3 | 3.07 (0.15) |
| Eyelid oedema | Immune system disorders | 6 | 2.43 (0.13) |
| Small intestinal obstruction | Gastrointestinal disorders | 5 | 2.59 (0.13) |
| Blood creatine increased | Investigations | 3 | 3.02 (0.11) |
| Gastrointestinal perforation | Gastrointestinal disorders | 3 | 3 (0.09) |
| Agranulocytosis | Blood and lymphatic system disorders | 6 | 2.38 (0.09) |
| Haematuria | Renal and urinary disorders | 11 | 1.89 (0.09) |
| Conjunctivitis | Eye disorders | 6 | 2.36 (0.07) |
| Metastatic neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 3 | 2.98 (0.06) |
| Acute kidney injury | Renal and urinary disorders | 14 | 1.65 (0.03) |